Clinical Trials for Colon Cancer

An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with metastatic melanoma, colorectal cancer, pancreatic ductal adenocarcinoma, or head and neck squamous cell carcinoma harboring MAPK-pathway mutations and no suitable standard options receive oral IPN01194 monotherapy, an ERK1/2 (MAPK1/3) inhibitor targeting the terminal RAS–RAF–MEK–ERK pathway. Dose-escalation identifies two doses, followed by randomized expansion in a single tumor type to assess activity.

ClinicalTrials.gov ID: NCT06305247

A Phase 1/2a First-In-Human, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CT3001 in Patients with Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with advanced/unresectable or metastatic solid tumors (dose-escalation), followed by expansion in refractory colorectal cancer or pancreatic ductal adenocarcinoma, receive CT3001, an oral first-in-class GPR35 inhibitor designed to modulate Hippo–YAP signaling and counter IDO1-mediated immune escape. Dosed once or twice daily in 21-day cycles to establish MTD/RP2D and assess preliminary activity.

ClinicalTrials.gov ID: NCT06598007

A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants With Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with unresectable advanced/metastatic MSI‑H or dMMR solid tumors (post anti–PD‑(L)1 unless ineligible) receive the first‑in‑human Werner (WRN) helicase inhibitor MOMA‑341 orally as monotherapy or combined with irinotecan or a checkpoint inhibitor. Aims include defining a recommended dose and early activity, with key exclusions such as active CNS progression and significant cardiac disease; ECOG 0–2 required.

ClinicalTrials.gov ID: NCT06974110

A Phase 1 Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with unresectable or metastatic NSCLC (including EGFR-known), colorectal cancer (with KRAS/NRAS/BRAF status known), or head and neck squamous cell carcinoma, ECOG 0–1, receive monotherapy with JNJ-95437446, an investigational antibody–drug conjugate with undisclosed target and payload, in dose escalation and disease-specific expansion. Excludes prior ILD/pneumonitis requiring steroids and other significant comorbidities; RECIST-measurable disease required in expansion cohorts.

ClinicalTrials.gov ID: NCT07107230

A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with advanced, unresectable or metastatic solid tumors across multiple cohorts (e.g., gastric/EGJ, colorectal, pancreatic, sarcoma, mesothelioma, neuroendocrine, cutaneous/anal SCC, Merkel cell, MMR‑deficient/MSI cancers) after standard therapy, ECOG 0–1; stable small brain mets allowed. Treatment is autologous tumor-infiltrating lymphocyte (TIL) therapy (tumor harvest → ex vivo expansion) after cyclophosphamide/fludarabine lymphodepletion, followed by high-dose aldesleukin (IL-2) to support T-cell expansion; single course with option for a second.

ClinicalTrials.gov ID: NCT03935893

A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Optimization Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB365 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies With KRAS G12S or G12C Mutations

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with unresectable/metastatic solid tumors harboring KRAS G12C or G12S are eligible for weekly IV KQB365 monotherapy across tumor types, with colorectal adenocarcinoma cohorts receiving KQB365 plus cetuximab; measurable disease and adequate organ function required, excluding active CNS primaries and significant ILD/cardiac disease. KQB365 is an investigational KRAS mutation–targeted agent (precise modality undisclosed) aimed at G12C/G12S; the study defines dose and evaluates early activity, with cetuximab added in CRC to counter EGFR feedback.

ClinicalTrials.gov ID: NCT06720987

Phase 1a/1b Study of CT-95 in Advanced Cancers Associated With Mesothelin Expression

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with mesothelin-expressing advanced solid tumors (ECOG 0–1) receive weekly IV CT-95 (LNK-101), a mesothelin × CD3 T‑cell–engaging bispecific antibody engineered for reduced off‑tumor activation, in a dose-escalation/expansion study. Excludes prior mesothelin-targeted CD3/CAR‑T therapy; evaluates safety, PK, and preliminary efficacy across tumor types including mesothelioma.

ClinicalTrials.gov ID: NCT06756035

Phase I/ II Study of Pulmonary Suffusion to Control Minimal Residual Disease in Resectable or Ablatable Sarcoma or Colorectal Pulmonary Metastases

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with resectable or ablatable pulmonary metastases from soft tissue sarcoma, osteosarcoma, or colorectal cancer undergo regional isolated lung perfusion (“pulmonary suffusion”) with cisplatin followed by complete local control (metastasectomy/ablation), aiming to reduce intrapulmonary recurrence while limiting systemic toxicity. Eligible patients have ECOG 0–2 and adequate pulmonary function; bilateral disease may allow within-patient comparison of suffused vs non-suffused lungs.

ClinicalTrials.gov ID: NCT03965234

A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with incurable, locally advanced or metastatic solid tumors (e.g., NSCLC, HNSCC, melanoma, TNBC, GI, cervical, CRC, urothelial, clear cell RCC, HCC) receive RO7502175, an afucosylated anti-CCR8 IgG1 designed to deplete intratumoral Tregs via enhanced ADCC, as monotherapy or combined with PD-(L)1 inhibitors (atezolizumab or pembrolizumab). Eligible patients have ECOG 0–1, measurable disease, and no active infections, autoimmune disease, or untreated CNS metastases.

ClinicalTrials.gov ID: NCT05581004

A Phase I/II Trial of Cabozantinib in Combination with Durvalumab (MEDI4736) with or Without Tremelimumab in Patients with Advanced Gastroesophageal Cancer and Other Gastrointestinal (GI) Malignancies (CAMILLA)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with ECOG 0–1 and advanced/unresectable gastric/GEJ or esophageal adenocarcinoma (post ≥1 line), colorectal adenocarcinoma (post ≥2 lines; anti-EGFR if RAS WT), or hepatocellular carcinoma (treatment‑naive or previously treated) receive cabozantinib (MET/VEGFR2/AXL multikinase inhibitor) plus durvalumab (PD‑L1 inhibitor), with an HCC cohort also getting a single priming dose of tremelimumab (CTLA‑4 antibody). Baseline/on‑treatment biopsies required; prior PD‑1/PD‑L1 generally excluded except per HCC and gastric/esophageal protocol allowances.

ClinicalTrials.gov ID: NCT03539822